Lingaliptin (Trajenta) DPP4 inhibitor is CV neutral in CARMELINA trial results presented just now at EASD 2018, similar to other previous DPP4 inhibitor CVOTs. CARMELINA primary goal was to shown cardio and renal safety, not to show reduced cardiovascular events or improved renal function. Both Lilly and Boehringer Ingelheim just issued press releases. Also, the CVD-REAL presentation on SGLT2 inhibitors this morning didn't create a lot of buzz, so probably nothing new presented.